Cachexia as a major underestimated and unmet medical need: facts and numbers
- PMID: 21475699
- PMCID: PMC3060651
- DOI: 10.1007/s13539-010-0002-6
Cachexia as a major underestimated and unmet medical need: facts and numbers
Abstract
Cachexia is a serious, however underestimated and underrecognised medical consequence of malignant cancer, chronic heart failure (CHF), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, rheumatoid arthritis, Alzheimer's disease, infectious diseases, and many other chronic illnesses. The prevalence of cachexia is high, ranging from 5% to 15% in CHF or COPD to 60% to 80% in advanced cancer. By population prevalence, the most frequent cachexia subtypes are in order: COPD cachexia, cardiac cachexia (in CHF), cancer cachexia, and CKD cachexia. In industrialized countries (North America, Europe, Japan), the overall prevalence of cachexia (due to any disease) is growing and currently about 1%, i.e., about nine million patients. The relative prevalence of cachexia is somewhat less in Asia, but is a growing problem there as well. In absolute terms, cachexia is, in Asia (due to the larger population), as least as big a problem as in the Western world. Cachexia is also a big medical problem in South America and Africa, but data are scarce. A consensus statement recently proposed to diagnose cachexia in chronic diseases when there is weight loss exceeding 5% within the previous 3-12 months combined with symptoms characteristic for cachexia (e.g., fatigue), loss of skeletal muscle and biochemical abnormalities (e.g., anemia or inflammation). Treatment approaches using anabolics, anti-catabolic therapies, appetite stimulants, and nutritional interventions are under development. A more thorough understanding of the pathophysiology of cachexia development and progression is needed that likely will lead to combination therapies being developed. These efforts are greatly needed as presence of cachexia is always associated with high-mortality and poor-symptom status and dismal quality of life. It is thought that in cancer, more than 30% of patients die due to cachexia and more than 50% of patients with cancer die with cachexia being present. In other chronic illnesses, one can estimate that up to 30% of patients die with some degree of cachexia being present. Mortality rates of patients with cachexia range from 10% to 15% per year (COPD), to 20% to 30% per year (CHF, CKD) to 80% in cancer.
Similar articles
-
Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016.J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509. doi: 10.1002/jcsm.12167. Epub 2016 Nov 2. J Cachexia Sarcopenia Muscle. 2016. PMID: 27891294 Free PMC article.
-
Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact.J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):515-519. doi: 10.1002/jcsm.12117. Epub 2016 Apr 12. J Cachexia Sarcopenia Muscle. 2016. PMID: 27239422 Free PMC article.
-
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014.J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):261-3. doi: 10.1007/s13539-014-0164-8. J Cachexia Sarcopenia Muscle. 2014. PMID: 25384990 Free PMC article.
-
The syndrome of cardiac cachexia.Int J Cardiol. 2002 Sep;85(1):51-66. doi: 10.1016/s0167-5273(02)00233-4. Int J Cardiol. 2002. PMID: 12163209 Review.
-
Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation.Chest. 1999 Mar;115(3):836-47. doi: 10.1378/chest.115.3.836. Chest. 1999. PMID: 10084500 Review.
Cited by
-
Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia.Cells. 2024 May 3;13(9):783. doi: 10.3390/cells13090783. Cells. 2024. PMID: 38727319 Free PMC article.
-
Effects of Adjuvant Exercise and Nutrition Therapy on Muscle Fibre Biomechanics in Gastrointestinal Cancer Patients.Cancers (Basel). 2024 Apr 22;16(8):1608. doi: 10.3390/cancers16081608. Cancers (Basel). 2024. PMID: 38672689 Free PMC article.
-
Qualitative interviews of patients with COPD and muscle weakness enrolled in a clinical trial evaluating a new anabolic treatment: patient perspectives of disease experience, trial participation and outcome assessments.J Patient Rep Outcomes. 2024 Apr 20;8(1):45. doi: 10.1186/s41687-024-00712-0. J Patient Rep Outcomes. 2024. PMID: 38641716 Free PMC article.
-
Comparison of the cachexia index based on hand-grip strength (H-CXI) with the original CXI for the prediction of cancer cachexia and prognosis in patients who underwent radical colectomy for colorectal cancer.Front Nutr. 2024 Feb 20;11:1290299. doi: 10.3389/fnut.2024.1290299. eCollection 2024. Front Nutr. 2024. PMID: 38445206 Free PMC article.
-
Management of cancer cachexia towards optimizing care delivery and patient outcomes.Asia Pac J Oncol Nurs. 2023 Oct 21;10(Suppl 1):100322. doi: 10.1016/j.apjon.2023.100322. eCollection 2023 Nov. Asia Pac J Oncol Nurs. 2023. PMID: 38197039 Free PMC article. Review.
References
-
- Müller H (2009) Atemschaukel. München
LinkOut - more resources
Full Text Sources
Other Literature Sources